Apogee Therapeutics reported that its Phase 1b study of APG777 (zumilokibart) in 19 adults with mild‑to‑moderate asthma produced encouraging interim data. Each participant received a single 720 mg dose and was followed for 32 weeks. The study demonstrated rapid and durable suppression of fractional exhaled nitric oxide (FeNO), a key biomarker of type‑2 airway inflammation, for all patients through 16 weeks and for those with available data through 32 weeks. Safety data were favorable; no serious adverse events were observed and the only treatment‑emergent adverse event reported in more than one patient was gastro‑oesophageal reflux disease in two participants.
The results reinforce APG777’s “pipeline‑in‑a‑product” concept, showing that a single antibody can be leveraged across multiple type‑2 inflammatory diseases. The durable FeNO suppression suggests the possibility of less frequent dosing—potentially every three to six months—an attractive feature that could differentiate the drug from existing IL‑13 inhibitors such as dupilumab, which require more frequent administration. The data also provide a foundation for dose‑finding and larger‑scale studies in asthma, while the company’s atopic dermatitis program continues to progress toward Phase 3 initiation in the second half of 2026 and a potential launch in 2029.
CEO Michael Henderson said the study “demonstrates the versatility of zumilokibart across Type 2 inflammatory diseases and gives us confidence to advance the platform in asthma.” Chief Medical Officer Carl Dambkowski added that the favorable safety profile and durable FeNO suppression “highlight the promise of this drug for asthma patients with Type 2 inflammation.” An independent pulmonologist, Mario Castro, noted that the data “showcase the potential of this treatment to help a new patient population, especially those who would benefit from less frequent administration.”
Analysts responded positively to the data, raising price targets and maintaining buy ratings in light of the strong clinical signal and the company’s robust cash position. The positive interim results have bolstered confidence in Apogee’s strategy to develop a platform antibody that can be applied across multiple indications.
Apogee’s cash balance stood at $913 million as of September 30 2025, giving the company a runway into the second half of 2028. The strong liquidity position supports continued investment in late‑stage trials and the planned Phase 3 program for atopic dermatitis, while also providing flexibility to pursue additional indications such as eosinophilic esophagitis.
The company plans to report Phase 2 data for its atopic dermatitis program in the first half of 2026 and to initiate a Phase 3 program for asthma later in the year. A potential launch for zumilokibart in atopic dermatitis is anticipated in 2029, positioning the drug as a long‑term treatment option across several inflammatory diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.